BioSpace News Archive

Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, announced the closing of the first tranche of €22 million as part of its Series D financing round that could reach up to €52 million in total.

Metagenomi Presents New Preclinical Data at ASGCT on Proprietary, Highly Efficient CRISPR Gene Editing Systems and a Novel Family of CRISPR-Associated Transposases (CASTs).

Nuritas, a biotechnology company using AI to revolutionize the discovery of untapped, natural, bioactive peptides, announced it will build its North American headquarters in Connecticut, near Yale University.

Proscia® , a leader in digital and computational pathology solutions, has introduced an automated quality control application that leverages artificial intelligence to improve quality and efficiency in data-driven drug development.

Neuronetics, Inc. announced a new peer-reviewed paper, published in Brain Stimulation Journal and available online now.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the Company recently participated in a mid-cycle communication meeting with the U.S. Food & Drug Administration (FDA) and was informed that the Agency plans to convene an Advisory Committee meeting for the New Drug Application (NDA) for omecamtiv mecarbil.

Accuray Incorporated (NASDAQ: ARAY) announced today that Sandeep Chalke has joined the company as senior vice president, chief commercial officer effective May 16, 2022 .

SwanBio Therapeutics, a gene therapy company advancing adeno-associated virus (AAV)-based therapies for the treatment of devastating, inherited neurological conditions, today presented additional details from studies of SBT101.

Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., welcomes the recently announced public formulary coverage for AJOVY® (fremanezumab) by Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland.

Histogen Inc. announced that Steven J. Mento, Ph.D., Histogen’s Executive Chairman and Interim President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference.